Jiangsu Alphamab Biopharmaceuticals Co., Ltd

This trial compares an experimental drug called JSKN033 with standard chemotherapy in people whose cervical cancer has returned or spread and no longer responds to platinum-based chemotherapy or PD-1/L1 inhibitors. The study includes about 368 adults with recurrent or metastatic …

This study tests whether adding the experimental drug JSKN033 to standard chemotherapy (with or without bevacizumab) is safe and effective for people with advanced cervical cancer that has spread or come back. About 78 adults will take part. The goal is to control the disease and…

This early-phase study tests a new drug called JSKN016HC in about 42 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants must be in fairly …

This early-phase study tests a new drug called JSKN027 in 250 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. The study focuses on colorectal, lun…

This study tests a new two-drug combination (JSKN016 plus D-0502) in 60 people with advanced hormone receptor-positive, HER2-negative breast cancer whose disease worsened after standard hormone therapy. The goal is to see if the combination is safe and shrinks tumors. Participant…

This Phase 2 trial tests JSKN033, a combination of two drugs (a HER2-targeted antibody-drug conjugate and a PD-L1 inhibitor), in 160 people with advanced non-small cell lung cancer that cannot be cured. The study will first find the best dose, then expand to see how well it shrin…